报价延迟最少15分钟:2025/07/21 06:40 EDT
盘前时段
|
||||
|
2.22 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.22
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.63/1.13
|
|
企业价值
11.36M
|
| 资产负债 |
|
每股账面净值
-0.27
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/21 06:40 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD. |
